1. A phase 1 clinical trial evaluating marizomib, pomalidomide and low-dose dexamethasone in relapsed and refractory multiple myeloma ( NPI-0052-107): final study results.
- Author
-
Spencer, Andrew, Harrison, Simon, Zonder, Jeffrey, Badros, Ashraf, Laubach, Jacob, Bergin, Krystal, Khot, Amit, Zimmerman, Todd, Chauhan, Dharminder, Levin, Nancy, MacLaren, Ann, Reich, Steven D., Trikha, Mohit, and Richardson, Paul
- Subjects
- *
MULTIPLE myeloma treatment , *CANCER relapse , *PROTEASOME inhibitors , *GLIOMA treatment , *DEXAMETHASONE , *ANTINEOPLASTIC agents , *DRUG side effects , *THERAPEUTICS , *CANCER treatment - Abstract
Marizomib ( MRZ) is an irreversible, pan-subunit proteasome inhibitor ( PI) in clinical development for relapsed/refractory multiple myeloma ( RRMM) and glioma. This study analysed MRZ, pomalidomide ( POM) and low-dose dexamethasone (Lo- DEX) [ PMD] in RRMM to evaluate safety and determine the maximum tolerated dose ( MTD) and/or recommended Phase 2 dose ( RP2D). Intravenous MRZ (0·3-0·5 mg/m2) was administered over 2 h on days 1, 4, 8, 11; POM (3-4 mg) on days 1-21; and Lo- DEX (5 or 10 mg) on days 1, 2, 4, 5, 8, 9, 11, 12, 15, 16, 22 and 23 of every 28-day cycle. Thirty-eight patients were enrolled that had received a median of 4 (range 1-10) prior lines of therapy; all patients received prior lenalidomide and bortezomib. No dose-limiting toxicities ( DLTs) were observed and 0·5 mg/m2 MRZ was determined to be the RP2D. The most common treatment-related ≥Grade 3 adverse events were: neutropenia (11/38 patients: 29%), pneumonia (4/38 patients 11%), anaemia (4/38 patients; 11%) and thrombocytopenia (4/38 patients; 11%). The overall response rate and clinical benefit rate was 53% (19/36) and 64% (23/36), respectively. In conclusion, PMD was well tolerated and demonstrated promising activity in heavily pre-treated, high-risk RRMM patients. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF